Abstract

Type I interferons (IFNα and β) are induced directly in response to viral infection, resulting in an antiviral state for the cell. In vitro studies have shown that IFNα is a potent inhibitor of viral replication; however, its role in HIV-1 infection is incompletely understood. In this study we describe the ability of IFNα to restrict HIV-1 infection in primary human macrophages in contrast to peripheral blood mononuclear cells and monocyte-derived dendritic cells. Inhibition to HIV-1 replication in cells pretreated with IFNα occurred at an early stage in the virus life cycle. Late viral events such as budding and subsequent rounds of infection were not affected by IFNα treatment. Analysis of early and late HIV-1 reverse transcripts and integrated proviral DNA confirmed an early post entry role for IFNα. First strand cDNA synthesis was slightly reduced but late and integrated products were severely depleted, suggesting that initiation or the nucleic acid intermediates of reverse transcription are targeted. The depletion of integrated provirus is disproportionally greater than that of viral cDNA synthesis suggesting the possibility of a least an additional later target. A role for either cellular protein APOBEC3G or tetherin in this IFNα mediated restriction has been excluded. Vpu, previously shown by others to rescue a viral budding restriction by tetherin, could not overcome this IFNα induced effect. Determining both the viral determinants and cellular proteins involved may lead to novel therapeutic approaches. Our results add to the understanding of HIV-1 restriction by IFNα.

Highlights

  • Type I interferon (IFN) a and b can be induced directly in response to viral infection and trigger the transcription of a diverse range of IFN-stimulated genes (ISGs) through activation of the Jak-STAT pathway [1]

  • Monocyte-derived macrophages (MDM), Peripheral blood mononuclear cells (PBMC) and MDDC were infected with HIV-1 89.6 in the presence or absence of IFNa

  • Fold reduction is the ratio of focus forming units (FFU)/ml of no IFN compared to IFNa treated cells

Read more

Summary

Introduction

Type I interferon (IFN) a and b can be induced directly in response to viral infection and trigger the transcription of a diverse range of IFN-stimulated genes (ISGs) through activation of the Jak-STAT (signal transducer and activator transcription) pathway [1]. Overall, compared with the efficacy seen in treatment of viral infections such as Hepatitis C, the in vivo effects of IFNa in HIV-1 infected patients were modest at best, with conflicting results for negative outcomes such as toxicity, antiretroviral treatment failure and progression of HIV-1 disease. This was somewhat surprising as in vitro studies in both cell lines and primary human cells showed that IFNa is a potent inhibitor of HIV-1 infection, in the early stages [7,8,9,10,11,12,13,14]. The role of IFNa in HIV-1 infection is incompletely understood, results from this and other studies suggest that IFNa may regulate the expression of a restriction factor/s able to inhibit the replication of HIV-1

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.